A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 2,053 shares of SRPT stock, worth $316,572. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,053
Holding current value
$316,572
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

BUY
$93.7 - $141.53 $192,366 - $290,561
2,053 New
2,053 $265,000
Q3 2023

Nov 13, 2023

SELL
$102.5 - $123.59 $2.01 Million - $2.42 Million
-19,577 Reduced 19.95%
78,566 $9.52 Million
Q2 2023

Aug 10, 2023

SELL
$106.4 - $157.19 $2.29 Million - $3.38 Million
-21,523 Reduced 17.99%
98,143 $11.2 Million
Q1 2023

May 09, 2023

BUY
$117.53 - $155.99 $396,076 - $525,686
3,370 Added 2.9%
119,666 $16.5 Million
Q4 2022

Feb 10, 2023

SELL
$100.86 - $132.13 $4.18 Million - $5.47 Million
-41,435 Reduced 26.27%
116,296 $15.1 Million
Q3 2022

Nov 10, 2022

BUY
$75.71 - $119.24 $10.6 Million - $16.7 Million
139,890 Added 784.09%
157,731 $17.4 Million
Q2 2022

Aug 05, 2022

BUY
$62.69 - $88.44 $1.12 Million - $1.58 Million
17,841 New
17,841 $1.34 Million
Q2 2021

Aug 12, 2021

SELL
$69.38 - $86.75 $359,665 - $449,712
-5,184 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$72.25 - $168.95 $164,152 - $383,854
-2,272 Reduced 30.47%
5,184 $386,000
Q4 2020

Feb 16, 2021

SELL
$125.56 - $178.74 $130,707 - $186,068
-1,041 Reduced 12.25%
7,456 $1.27 Million
Q3 2020

Nov 12, 2020

BUY
$127.12 - $172.34 $1.08 Million - $1.46 Million
8,497 New
8,497 $1.19 Million
Q4 2018

Feb 12, 2019

SELL
$97.32 - $148.76 $150,846 - $230,578
-1,550 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$115.31 - $161.51 $178,730 - $250,340
1,550 New
1,550 $250,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $13.5B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.